PBYI - Puma Biotechnology Inc logo

Puma Biotechnology Inc

PBYI

Puma Biotechnology develops and commercializes cancer treatments, including NERLYNX for early-stage and advanced HER2-positive breast cancer. It also works on alisertib for various cancer types, using specialty pharmacy networks for distribution.

βš•οΈ Healthcare NASDAQ Listed 2012 $ USD
$1,000 invested 10 years ago β†’$259today

Score Overview

1 Year
Score
Net Growth-14.12%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth1.26%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score6.0
Net Growth191.73%
Net Trend67%
Net Income Consistencyβ€”
Rev Growth-8.66%
Rev Trend40%
Revenue Consistencyβ€”
10 Years
Scoreβ€”
Net Growth109.68%
Net Trend75%
Net Income Consistency
Rev Growthβ€”
Rev Trend60%
Revenue Consistency
All Time
Scoreβ€”
Net Growth135.96%
Net Trend58%
Net Income Consistency
Rev Growthβ€”
Rev Trend43%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Puma Biotechnology Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. PBYI does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 11.26β€”
1 Year2025-10-22
$ 5.23115.30%
5 Years2021-10-22
$ 5.6997.89%
10 Years2016-10-21
$ 43.55-74.14%
All Time2012-04-24
$ 14.00-19.57%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 231M$ 26M$ 93M
2025$ 228M$ 31M$ 97M
2024$ 230M$ 30M$ 100M
2023$ 235M$ 21M$ 95M
2022$ 228M$ 81M
2021$ 253M-$ 29M$ 82M
2020$ 225M-$ 59M$ 93M
2019$ 272M-$ 75M$ 111M
2018$ 251M-$ 113M$ 108M
2017$ 27M-$ 292M$ 81M
2016$ 0.00-$ 276M$ 194M
2015$ 0.00-$ 239M$ 31M
2014$ 0.00-$ 142M$ 38M
2013$ 0.00-$ 54M$ 83M
IPO2012$ 0.00-$ 74M$ 137M
PBYI - Puma Biotechnology Inc logo

Puma Biotechnology Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 225M to $ 228M and net income went from -$ 59M to $ 31M. Revenue increased in 2 of those 5 years; net income in 3.

Puma Biotechnology Inc currently holds a 5-year HDB Score of 6.0 out of 10. How the HDB Score is calculated.

Membership

Explore PBYI with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies